ClinicalTrials.gg
Not yet recruitingNCT06015074Updated May 31, 2024

Ciprofol vs Propofol for Reducing Hypoxia Incidence in ERCP

An interventional study of Propofol and Ciprofol in Anesthesia; Adverse Effect and Biliary Tract Diseases, sponsored by RenJi Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-31.

Sponsored by RenJi Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Intravenous anesthesia has been widely used in endoscopic retrograde cholangiopancreatography (ERCP). In the past decade, many practices have been carried out under the propofol-based monitored anesthesia care without endotracheal intubation in patients undergoing ERCP.

Ciprofol is a newly developed intravenous anesthetic with a potency 4-5 times than that of propofol. Ciprofol seems a promising anesthetic agent for intravenous anesthesia but the evidence supported its application in ERCP is still limited.

Read the detailed description

This is a prospective, randomized, double-blind trial comparing the incidence of hypoxia in the propofol versus ciprofol intravenous Anesthesia. A total 136 patients will be recruited and randomly assigned to either the propofol or the ciprofol group. The primary outcome is the proportion of patients experiencing hypoxia. The secondary outcomes include: the incidence of hypotension in perioperative period; the incidence of conversion from intravenous anesthesia to general anesthesia; sedation-related procedure interruption; carbon dioxide( CO2) accumulation during operation; Patients' satisfaction with anesthesia and postoperative recovery / VAS score / incidence of nausea and vomiting; the incidence of intraoperative and postoperative adverse events, such as adverse excretion, severe hypoxemia, severe circulatory dysfunction; length of stay and mortality within 30 days after operation.

02

Conditions studied

  • Anesthesia; Adverse Effect
  • Biliary Tract Diseases

Keywords

  • Ciprofol
  • Propofol
  • Intravenous Anesthesia
  • Elective Endoscopic Retrograde Cholangiopancreatography
  • Hypoxia
03

In context

Biliary Tract Diseases

59 studies on the registry are indexed under Biliary Tract Diseases; 12 are open to participants now.

This study's planned enrollment of 136 is above the median of 84 across 37 interventional studies indexed under Biliary Tract Diseases.

Browse Biliary Tract Diseases studies →

Lead sponsor

RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients undergoing ERCP,
  • normal renal function
  • ≥ 18kg/m 2 and ≤ 30kg/m 2

Exclusion criteria

Exclusion Criteria:

  • Previous serious cerebrovascular accidents and other neurological diseases
  • mental diseases, long-term use of drugs that affect the function of the central nervous system, benzodiazepines or opioids
  • history of anesthetic allergy
  • preoperative hypotension or preoperative SpO2 \< 90%, or chronic respiratory failure
  • patients suspected of having difficult airways
  • screening for drug addiction and alcohol abuse within the first 3 months (> = 6standarddrinks/day)
  • patients diagnosed with severe cardiopulmonary disease, or respiratory or respiratory diseases such as sleep apnea syndrome;
  • bradycardia or atrioventricular block.
  • participate in other clinical trials within 4 weeks;
  • cognitive or communication abnormalities determined by the researchers;
  • emergent and critical conditions during the operation;
  • other conditions that the researchers believe are not suitable to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
136 participants (estimated)

Study arms

  • Active comparator
    Propofol group

    patients in Propofol group receive sufentanil+ propofol

    Drug: Propofol

  • Experimental
    Ciprofol group

    patients in Ciprofol group receive sufentanil+ ciprofol

    Drug: Ciprofol

Interventions

  • patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.

    Also known as: Fresenius Kabi,China

  • patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.

    Also known as: Haisike,China

06

What researchers measure

Primary outcomes

  1. the incidence of hypoxia

    the definition of hypoxemia: any event of SpO2 (oxygen saturation measured by pulse oximetry) \< 90%

    Time frame: from the induction of anesthesia to the patient leaving the postanesthesia care unit,about an average of 1.5 hours

Secondary outcomes

  1. the incidence of hypercapnia

    arterial carbon dioxide partial pressure(PaCO2)\>50mmHg

    Time frame: 5 minutes each time(base line, 10 minutes after beginning of surgery, completion of surgery, 10 minutes after awakening)

  2. the incidence of hypotension

    invasive systolic pressure\<90mmHg

    Time frame: from the induction of anesthesia to the patient leaving the postanesthesia care unit,about an average of 1.5 hours

  3. sedation-related procedure interruption

    the incidence of interruption of procedure due to intolerance or severe adverse events

    Time frame: from the induction of anesthesia to completion of ERCP, about 30 minutes

  4. conversion from intravenous anesthesia to general anesthesia

    the incidence of conversion from intravenous anesthesia to general anesthesia due to intolerance or severe adverse events

    Time frame: from the induction of anesthesia to completion of ERCP, about 30 minutes

  5. patient satisfaction score

    Patients' satisfaction score is measured by patient recovery satisfaction score, from -33 the worst to 33 the best.

    Time frame: 5 minutes

  6. visual analog scale (VAS) scores

    perioperative pain is measured by visual analog scale (VAS) scores,from painless score 0 to the imagined most severe pain score 10

    Time frame: 30 seconds

  7. length of stay

    length of stay in hospital

    Time frame: 2-7days

  8. the incidence of postoperative adverse bile excretion

    patients with symptoms or signs of postoperative adverse bile excretion

    Time frame: 30 days after operation

  9. the incidence of severe postoperative hypoxia

    patients with symptoms or signs of severe postoperative hypoxia

    Time frame: 30 days after operation

  10. the incidence of severe postoperative circulatory disfunction

    patients with symptoms or signs of severe postoperative circulatory disfunction

    Time frame: 30 days after operation

  11. the incidence of mortality within 30 days after operation

    mortality within 30 days after operation

    Time frame: 30 days after operation

07

Study locations

1 site
08

References and documents

Publications

  • Adler DG, Baron TH, Davila RE, Egan J, Hirota WK, Leighton JA, Qureshi W, Rajan E, Zuckerman MJ, Fanelli R, Wheeler-Harbaugh J, Faigel DO; Standards of Practice Committee of American Society for Gastrointestinal Endoscopy. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc. 2005 Jul;62(1):1-8. doi: 10.1016/j.gie.2005.04.015. No abstract available. PubMed 15990812 ↗
  • Alzanbagi AB, Jilani TL, Qureshi LA, Ibrahim IM, Tashkandi AMS, Elshrief EEA, Khan MS, Abdelhalim MAH, Zahrani SA, Mohamed WMK, Nageeb AM, Abbushi B, Shariff MK. Randomized trial comparing general anesthesia with anesthesiologist-administered deep sedation for ERCP in average-risk patients. Gastrointest Endosc. 2022 Dec;96(6):983-990.e2. doi: 10.1016/j.gie.2022.06.003. Epub 2022 Jun 9. PubMed 35690151 ↗
  • Cote GA, Hovis RM, Ansstas MA, Waldbaum L, Azar RR, Early DS, Edmundowicz SA, Mullady DK, Jonnalagadda SS. Incidence of sedation-related complications with propofol use during advanced endoscopic procedures. Clin Gastroenterol Hepatol. 2010 Feb;8(2):137-42. doi: 10.1016/j.cgh.2009.07.008. Epub 2009 Jul 14. PubMed 19607937 ↗
  • Amornyotin S, Srikureja W, Chalayonnavin W, Kongphlay S. Dose requirement and complications of diluted and undiluted propofol for deep sedation in endoscopic retrograde cholangiopancreatography. Hepatobiliary Pancreat Dis Int. 2011 Jun;10(3):313-8. doi: 10.1016/s1499-3872(11)60052-0. PubMed 21669577 ↗
  • Qadeer MA, Vargo JJ, Dumot JA, Lopez R, Trolli PA, Stevens T, Parsi MA, Sanaka MR, Zuccaro G. Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography. Gastroenterology. 2009 May;136(5):1568-76; quiz 1819-20. doi: 10.1053/j.gastro.2009.02.004. PubMed 19422079 ↗
  • Vargo JJ, Zuccaro G Jr, Dumot JA, Conwell DL, Morrow JB, Shay SS. Automated graphic assessment of respiratory activity is superior to pulse oximetry and visual assessment for the detection of early respiratory depression during therapeutic upper endoscopy. Gastrointest Endosc. 2002 Jun;55(7):826-31. doi: 10.1067/mge.2002.124208. PubMed 12024135 ↗
  • Paspatis GA, Manolaraki MM, Vardas E, Theodoropoulou A, Chlouverakis G. Deep sedation for endoscopic retrograde cholangiopancreatography: intravenous propofol alone versus intravenous propofol with oral midazolam premedication. Endoscopy. 2008 Apr;40(4):308-13. doi: 10.1055/s-2007-995346. Epub 2007 Dec 5. PubMed 18058653 ↗
  • Vargo JJ, Zuccaro G Jr, Dumot JA, Shermock KM, Morrow JB, Conwell DL, Trolli PA, Maurer WG. Gastroenterologist-administered propofol versus meperidine and midazolam for advanced upper endoscopy: a prospective, randomized trial. Gastroenterology. 2002 Jul;123(1):8-16. doi: 10.1053/gast.2002.34232. PubMed 12105827 ↗
  • Liu Y, Yu X, Zhu D, Zeng J, Lin Q, Zang B, Chen C, Liu N, Liu X, Gao W, Guan X. Safety and efficacy of ciprofol vs. propofol for sedation in intensive care unit patients with mechanical ventilation: a multi-center, open label, randomized, phase 2 trial. Chin Med J (Engl). 2022 May 5;135(9):1043-1051. doi: 10.1097/CM9.0000000000001912. PubMed 34924506 ↗
  • Liu Y, Chen C, Liu N, Tong L, Nie Y, Wu J, Liu X, Gao W, Tang L, Guan X. Efficacy and Safety of Ciprofol Sedation in ICU Patients with Mechanical Ventilation: A Clinical Trial Study Protocol. Adv Ther. 2021 Oct;38(10):5412-5423. doi: 10.1007/s12325-021-01877-6. Epub 2021 Aug 21. PubMed 34417990 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2024; primary completion for Dec 2024, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Aug 29, 2023
StartEst.
Jun 15, 2024
Primary completionEst.
Dec 31, 2024
CompletionEst.
Feb 28, 2025
Last update
May 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06015074
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Jun 15, 2024 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Feb 28, 2025 (estimated)
Last update
May 31, 2024

Study contacts

Peiying Li, Doctor
Contact
peiyingli.md@gmail.com
15800616866
Peiying Li, Doctor
study director · Clinial Research Center, Renji Hospital
Yu Weifeng, Doctor
study chair · Department of Anesthesiology, Renji Hospital
Zheng Li, Master
study director · Department of Anesthesiology, Renji Hospital
Yanhua Zhao, Doctor
principal investigator · Department of Anesthesiology, Renji Hospital
Yifeng Qu, Master
principal investigator · Department of Anesthesiology, Renji Hospital
Kun Luo, Master
principal investigator · Department of Anesthesiology, Renji Hospital
Guangyan Wang
principal investigator · Operating Room,Renji Hospital
Teng Wang
principal investigator · Department of Anesthesiology, Renji Hospital
Huichen Zhu, Master
principal investigator · Department of Anesthesiology, Renji Hospital
Jing Gao, Doctor
principal investigator · Clinial Research Center, Renji Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion